TB-500 Research Overview

TB-500 (also written without a hyphen, TB500), as specified for this listing, is synthetic full-length Thymosin Beta-4, a naturally occurring 43-amino-acid peptide involved in actin regulation and cell migration. The name TB-500 is also used elsewhere for a much shorter acetylated fragment, so the measured molecular mass on the lot COA is what confirms the material.

TB-500 has no approved human medical indication and has not been evaluated by the FDA or any other regulatory body for safety or efficacy in humans. Published research on TB-500 is overwhelmingly preclinical: conducted in vitro (cell and tissue culture) or in animal models, primarily rodents. We are not aware of well-controlled human clinical trials establishing a therapeutic effect for any condition.

Published research on Thymosin Beta-4, the molecule specified for this listing, is concentrated in a few recurring preclinical themes:

• Cell migration and actin regulation — in vitro studies have examined Thymosin Beta-4's role as an actin-sequestering protein and its effects on cell motility, the mechanistic basis for most downstream research interest in this peptide.
• Cardiac tissue models — animal models of cardiac injury have investigated Thymosin Beta-4 in relation to post-injury vascular and tissue-repair signaling.
• Cutaneous and corneal wound models — rodent skin and corneal injury models have been used to study wound-healing-related endpoints associated with this peptide family.

These are summaries of published research topics, not claims about what this product does, and animal-model findings do not establish an effect in humans. See References below to search the primary literature directly.